Company overview
Nucleai provides AI-powered spatial biomarker and diagnostics solutions for biopharma, analyzing cellular interactions in tissue samples to advance drug development in oncology. Their platform uses deep learning for multiplex immunofluorescence analysis, automating normalization of high-plex imaging data to identify biomarkers for ADCs, bispecifics, immunotherapy, NSCLC, and melanoma. It enables precise prediction of treatment responses and scalable validation across cohorts.
AI-Driven Spatial Biomarkers is listed in the NovaPharmaNews Supplier Hub as a Diagnostics & Testing partner serving United States & Americas. Core focus areas include spatial biomarkers, ai pathology, multiplex immunofluorescence, oncology diagnostics, adc biomarkers.
Industry categories: Diagnostics & Testing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Products and technologies associated with AI-Driven Spatial Biomarkers include Diagnostic — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://nucleai.ai
- Categories
- Diagnostics & Testing
- Markets served
- United States & Americas
- Keywords
- spatial biomarkers, ai pathology, multiplex immunofluorescence, oncology diagnostics, adc biomarkers
Products & technologies
Therapeutic areas
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What are Nucleai's key capabilities in spatial biology?
- Nucleai leverages AI and geospatial methods to analyze multiplex immunofluorescence imaging, mapping cellular interactions and protein expression for biomarker discovery in oncology therapeutics like ADCs and immunotherapies.
- What therapeutic areas does Nucleai support?
- Nucleai focuses on precision oncology, providing spatial biomarkers for NSCLC, melanoma, ADCs, bispecific antibodies, and immunotherapy response prediction.
- Where is Nucleai headquartered and what is their geographical focus?
- Nucleai is headquartered in Tel Aviv, Israel, and serves global biopharma clients through AI-driven spatial analysis platforms applicable worldwide.
Related editorial coverage
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
Explore lab tools and QA/QC resources for R&D teams.
